(1)
Maji, D.; Samanta, S. A REVIEW ON THE ROLE OF PPARγ AGONISTS AND HYBRIDS IN TYPE 2 DIABETES AND CARDIOMYOPATHY. Asian J Pharm Clin Res 2015, 8, 26-31.